Patents by Inventor Diana Julie Leeming
Diana Julie Leeming has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240011997Abstract: Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying elastin fragments with a C-terminus amino acid sequence LPGGYGLPYT (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting or quantifying fibrotic diseases such as chronic obstructive lung disease (COPD).Type: ApplicationFiled: July 25, 2023Publication date: January 11, 2024Applicant: Nordic Bioscience A/SInventors: Karoline Natasja Stæhr Gudmann, Jannie Marie Bülow Sand, Tina Manon-Jensen, Diana Julie Leeming, Morten Karsdal
-
Publication number: 20240003906Abstract: The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.Type: ApplicationFiled: April 15, 2020Publication date: January 4, 2024Applicant: Nordic Bioscience A/SInventors: Martin Pehrsson, Morten Asser Karsdal, Diana Julie Leeming, Mette Juul Fisker, Tina Manon-Jensen, Joachim Høg Mortensen
-
Publication number: 20230184787Abstract: Disclosed herein are immunoassay methods for detecting and quantifying human neutrophil elastase (HNE) generated fragments of calprotectin in a biofluid sample; and monoclonal antibodies and assay kits for use in such methods. The methods may be used for detecting, monitoring and/or determining the status or severity of a disease characterized by or exhibiting inflammation in a patient.Type: ApplicationFiled: May 12, 2021Publication date: June 15, 2023Applicant: Nordic Bioscience A/SInventors: Joachim Høg Mortensen, Dovile Sinkeviciute, Tina Manon-Jensen, Morten Asser Karsdal, Anne-Christine Bay-Jensen, Signe Holm Nielsen, Annika Hummersgaard Hansen, Jannie Marie Bülow Sand, Diana Julie Leeming, Nicholas Willumsen, Christina Jensen
-
Publication number: 20210293828Abstract: A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibodyType: ApplicationFiled: June 4, 2021Publication date: September 23, 2021Applicant: NORDIC BIOSCIENCE A/SInventors: Jannie Marie Bülow SAND, Diana Julie LEEMING, Morten KARSDAL
-
Publication number: 20190195875Abstract: A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibodyType: ApplicationFiled: January 20, 2017Publication date: June 27, 2019Applicant: NORDIC BIOSCIENCE A/SInventors: Jannie Marie Bülow SAND, Diana Julie LEEMING, Morten KARSDAL
-
Patent number: 9891234Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of mimecan, a protein of an atherosclerotic plaque, by a proteinase is provided. In the method a sample, such as urine or serum, is contacted with an antibody reactive with the neo-epitope and the level of binding of the antibody to peptide fragments in the sample is determined. The assay is predictive of risk of cardiovascular disease events.Type: GrantFiled: May 4, 2012Date of Patent: February 13, 2018Assignee: Nordic Biociences A/SInventors: Natasha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming
-
Patent number: 9726674Abstract: Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognize or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody.Type: GrantFiled: April 15, 2014Date of Patent: August 8, 2017Assignee: Nordic Bioscience A/SInventors: Diana Julie Leeming, Mette Juul Nielsen, Morten Karsdal
-
Patent number: 9500659Abstract: An immunoassay for the quantification of fragments having an N- or a C-terminal neo-epitope formed by cleavage of a titin protein by a proteinase is provided. The immunoassay includes the steps of contacting a sample with an antibody specifically binding to the N- or C-terminal neo-epitope of the fragments and determining the level of binding.Type: GrantFiled: July 6, 2012Date of Patent: November 22, 2016Assignee: Nordic Bioscience A/SInventors: Diana Julie Leeming, Morten Karsdal, Efstathios Vassiliadis
-
Publication number: 20160077108Abstract: Provided is an antibody which binds to an epitope of collagen type VI alpha 1 comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1). Also provided is a method of immunoassay for detecting in a biological sample an epitope comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1) of collagen type VI alpha 1, by contacting the sample with the antibody, and determining the amount of binding of the antibody.Type: ApplicationFiled: April 23, 2014Publication date: March 17, 2016Applicant: NORDIC BIOSCIENCE A/SInventors: Diana Julie Leeming, Anders Nedergaard, Morten Karsdal
-
Publication number: 20160061844Abstract: Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognise or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody.Type: ApplicationFiled: April 15, 2014Publication date: March 3, 2016Applicant: Nordic Bioscience A/SInventors: Diana Julie Leeming, Mette Juul Nielsen, Morten Karsdal
-
Publication number: 20150118698Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.Type: ApplicationFiled: May 4, 2012Publication date: April 30, 2015Applicant: Nordic Biociences A/SInventors: Natas[c]ha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming